Natixis
- SEC CIK
- 0001274981
- Latest filing
- Aug 13, 2026
BCRX holding history
Biocryst Pharmaceuticals Inc in every 13F filed by Natixis, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BCRX overviewAll 13F holders of BCRXFull Q2 2026 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q4 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −2,334−100.0% | Sold out | Holders |
| Q4 2024 | 2,334 | $17.6K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 2,334 | $17.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 2,334 | $14.4K | <0.1% | −9,350−80.0% | Reduced | Holders |
| Q1 2024 | 11,684 | $59.4K | <0.1% | +9,350+400.6% | Added | Holders |
| Q4 2023 | 2,334 | $14.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 2,334 | $16.5K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 2,334 | $16.4K | <0.1% | −593−20.3% | Reduced | Holders |
| Q1 2023 | 2,927 | $24.4K | <0.1% | −1,907−39.4% | Reduced | Holders |
| Q4 2022 | 4,834 | $55.5K | <0.1% | +4,834 | New | Holders |